Pharmacovigilance studies have reported an increasing incidence of atrial fibrillation, particularly with PD-1/PD-L1 inhibitors and with the ipilimumab–nivolumab combination, where the risk is significantly higher compared with monotherapy [31]. Here, CD274 is linked to atrial fibrillation.